Sapropterin dihydrochloride
盐酸沙丙蝶呤Oral BH4 therapy transitioning from the 2025 Commercial List (#2) into the 2026 NRDL Negotiated List (#42) with a published payment standard of ¥62.00 per 100mg tablet.
China Approval (NMPA)
Approved- Approval Number(s)
- 国药准字H20233796
- Initial Approval Date
- Jun 29, 2023
- Notice Published
- Jun 29, 2023
- MAH
- Shandong New Time Pharmaceutical Co., Ltd. (山东新时代药业有限公司)
- Approved Scope
- Treatment of hyperphenylalaninemia (HPA) due to tetrahydrobiopterin (BH4) deficiency in responsive patients (first domestic generic approval).
National Reimbursement
Announced · Effective Jan 1, 2027- 2026 Edition Entry
- Negotiated #42 · Class B
- Agreement Period
- 2027-01-01 to 2028-12-31
- Payment Standard
- 62.00元(100mg/片)
- 2026 Payment Scope
- Restricted to hyperphenylalaninemia (HPA) due to tetrahydrobiopterin (BH4) deficiency.
- 限四氢生物蝶呤(BH4)缺乏症所导致的高苯丙氨酸血症(HPA)。
Commercial Insurance List
2025 Only (Not in 2026)Previously listed in the 2025 Commercial Insurance Innovative Drug List (#2). Graduated into the 2026 Basic NRDL (#42).
Approved Products, Dosage Forms & Approval Numbers
1 verified NMPA record| Approval No. | Dosage Form & Strength | Event & Scope | Approval / Notice Date | MAH & Source |
|---|---|---|---|---|
| 国药准字H20233796 | Tablet (片剂) 100mg | Initial Approval Treatment of hyperphenylalaninemia (HPA) due to tetrahydrobiopterin (BH4) deficiency in responsive patients (first domestic generic approval). 适用于对本品治疗有反应的四氢生物蝶呤(BH4)缺乏症所导致的高苯丙氨酸血症(HPA)。 | Approved: 2023-06-29 Published: 2023-06-29 | Shandong New Time Pharmaceutical Co., Ltd. |
Change Timeline
- (2027-01-01)Basic NRDL· Catalog published: Nov 14, 2026
2026 NRDL · Added to Negotiated List
Newly added to 2026 NRDL Negotiated List (#42, Class B, ¥62.00 per 100mg tablet) for BH4-deficiency HPA; transitioned from the 2025 Commercial List (#2).
Chinese original: 由2025版商保创新药目录(第2项)转入2026版基本医保谈判药品第42项(乙类,62.00元/100mg片),限BH4缺乏症所致HPA。
NHSA · PDF p.120Verified 2026-11-20 - (2026-01-01)Commercial List· Catalog published: Dec 7, 2025
2025 Commercial List · Removed in 2026 Edition (#2)
Listed in 2025 Commercial List (#2) for BH4-responsive HPA; graduated into the 2026 basic NRDL Negotiated List (#42).
Chinese original: 适用于对本品治疗有反应的四氢生物蝶呤(BH4)缺乏症所导致的高苯丙氨酸血症(HPA),可用于成人及4岁以上儿童。
NHSA · PDF p.2Verified 2026-11-20 - (2023-06-29)NMPA Approval
NMPA Initial Marketing Approval (国药准字H20233796 · 100mg)
Treatment of hyperphenylalaninemia (HPA) due to tetrahydrobiopterin (BH4) deficiency in responsive patients (first domestic generic approval).
Chinese original: 适用于对本品治疗有反应的四氢生物蝶呤(BH4)缺乏症所导致的高苯丙氨酸血症(HPA)。
NMPA · NMPA Registration H20233796Verified 2026-11-21
Verified Names & Aliases
Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.
Primary Sources for This Record
- NHSAPublished 2026-11-14国家基本医疗保险、生育保险和工伤保险药品目录(2026年)Retrieved 2026-11-20
- NHSAPublished 2025-12-07商业健康保险创新药品目录(2025年)Retrieved 2026-11-20 · 医保发〔2025〕33号附件
- NMPA国家药品监督管理局政务服务门户与药品查询Retrieved 2026-11-20